advertising
-
1
Baer WS: The treatment of chronic osteomyelitis with the maggot. .J Bone Joint Surg 13::438. ,1931. .
-
2
Root-Bernstein R: Honey, Mud, Maggots and Other Medical Marvels: The Science Behind Folk Remedies and Old Wives’ Tales, Houghton Mifflin Co, Boston. ,1997. .
-
3
Claxton MJ, Armstrong DG, Short B, et al: 5 questions—and answers—about maggot debridement therapy. .Adv Wound Care 16::99. ,2003. .
-
4
Armstrong DG, Mossel J, Nixon BP, et al: Maggot debridement therapy: a primer. .JAPMA 92::398. ,2002. .
-
5
Bunkis J, Gherini S, Walton RL: Maggot therapy revisited. .West J Med 142::554. ,1985. .
-
6
Sherman RA: Use of Medicinal Maggots, University of California, Irvine. ,2002. .
-
7
Sherman RA, Sherman J, Gilead L, et al: Maggot debridement therapy in outpatients. .Arch Phys Med Rehabil 82::1226. ,2001. .
-
8
Mumcuoglu KY, Ingber A, Gilead L, et al: Maggot therapy for the treatment of diabetic foot ulcers. .Diabetes Care 21::2030. ,1998. .
-
9
Mumcuoglu KY, Ingber A, Gilead L, et al: Maggot therapy for the treatment of intractable wounds. .Int J Dermatol 38::623. ,1999. .
-
10
Mumcuoglu KY, Miller J, Mumcuoglu M, et al: Destruction of bacteria in the digestive tract of the maggot of Lucilia sericata (Diptera: Calliphoridae). .J Med Entomol 38::161. ,2001. .
-
11
Armstrong DG, Lavery LA, Harkless LB: Validation of a diabetic wound classification system: the contribution of depth, infection, and vascular disease to the risk of amputation. .Diabetes Care 21::855. ,1998. .
-
12
Bongard O, Krahenbuhl B: Predicting amputation in severe ischemia: the value of transcutaneous PO2 measurement. .J Bone Joint Surg Br 70::465. ,1988. .
-
13
Hauser CJ, Klein SR, Mehringer CM, et al: Assessment of perfusion in the diabetic foot by regional transcutaneous oximetry. .Diabetes 33::527. ,1984. .
-
14
Forst T, Pfutzner A, Bauersachs R, et al: Comparison of the microvascular response to transcutaneous electrical nerve stimulation and postocclusive ischemia in the diabetic foot. .J Diabetes Comp 11::291. ,1997. .
-
15
Wyss CR, Matsen FA, Simmons CW, et al: Transcutaneous oxygen tension measurements on limbs of diabetic and nondiabetic patients with peripheral vascular disease. .Surgery 95::339. ,1984. .
-
16
International Working Group on the Diabetic Foot: International Consensus on the Diabetic Foot, International Working Group on the Diabetic Foot, Maastricht, the Netherlands. ,1999. .
-
18
Allon M: Prophylaxis against dialysis catheter-related bacteremia with a novel antimicrobial lock solution. .Clin Infect Dis 36::1539. ,2003. .
-
19
Jurewitsch B, Lee T, Park J, et al: Taurolidine 2% as an antimicrobial lock solution for prevention of recurrent catheter-related bloodstream infections. .JPEN J Parenter Enteral Nutr 22::242. ,1998. .
-
20
Lavery LA, Armstrong DG, Wunderlich RP, et al: Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. .Diabetes Care 26::1435. ,2003. .
Maggot Therapy in “Lower-Extremity Hospice” Wound Care
Fewer Amputations and More Antibiotic-Free Days
Department of Medicine, Manchester Royal Infirmary, Manchester, England.
Search for other papers by David G. Armstrong in
Current site
Google Scholar
PubMed
Search for other papers by Precious Salas in
Current site
Google Scholar
PubMed
Search for other papers by Brian Short in
Current site
Google Scholar
PubMed
Search for other papers by Billy R. Martin in
Current site
Google Scholar
PubMed
Search for other papers by Heather R. Kimbriel in
Current site
Google Scholar
PubMed
Search for other papers by Brent P. Nixon in
Current site
Google Scholar
PubMed
Diabetes Research Institute, University of Miami, Miami, FL.
Search for other papers by Andrew J. M. Boulton in
Current site
Google Scholar
PubMed
We sought to assess, in a case-control model, the potential efficacy of maggot debridement therapy in 60 nonambulatory patients (mean ± SD age, 72.2 ± 6.8 years) with neuroischemic diabetic foot wounds (University of Texas grade C or D wounds below the malleoli) and peripheral vascular disease. Twenty-seven of these patients (45%) healed during 6 months of review. There was no significant difference in the proportion of patients healing in the maggot debridement therapy versus control group (57% versus 33%). Of patients who healed, time to healing was significantly shorter in the maggot therapy than in the control group (18.5 ± 4.8 versus 22.4 ± 4.4 weeks). Approximately one in five patients (22%) underwent a high-level (above-the-foot) amputation. Patients in the control group were three times as likely to undergo amputation (33% versus 10%). Although there was no significant difference in infection prevalence in patients undergoing maggot therapy versus controls (80% versus 60%), there were significantly more antibiotic-free days during follow-up in patients who received maggot therapy (126.8 ± 30.3 versus 81.9 ± 42.1 days). Maggot debridement therapy reduces short-term morbidity in nonambulatory patients with diabetic foot wounds. (J Am Podiatr Med Assoc 95(3): 254–257, 2005)
advertising
